Unibest
← Back to patent-cliff list

Amrubicin Hydrochloride

Tier C — Watch / trade

Amrubicin Hydrochloride

Sumitomo Dainippon Pharma Co Ltd
Originator
2002
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type

Targets:TOP2

Brand:Amrubicin, Calsed

Indications (approved):Non-small cell lung cancer, Small cell lung cancer

Regional status

US
No progress
2006-11-01
EU
No progress
2006-11-01
China
No progress
2008-04-17
Japan
Approved
2002-04-11

Synthetic routes & intermediates1 routes

Originator routes × 1Optimised (non-patent) × 0Process routes × 0

Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.

OriginatorRoute 1Steps 10 · Total yield 1.12 g
AMRU-00137464-90-7AMRU-00299907-84-3AMRU-003—AMRU-004110267-86-2AMRU-00586264-61-1AMRU-00685-44-9AMRU-007104319-02-0AMRU-00886264-76-8AMRU-009110267-78-2AMRU-01092395-41-0AMRU-011—AMRU-012—API · Amrubicin Hydrochloride
CodeCAS No.Intermediate
AMRU-00137464-90-75,8-dimethoxy-3,4-dihydronaphthalen-2(1H)-one
AMRU-00299907-84-32-amino-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid
AMRU-003-methyl (R)-2-amino-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalene-2-carboxylate
AMRU-004110267-86-2(R)-1-(2-amino-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-yl)ethan-1-one
AMRU-00586264-61-1(R)-N-(2-acetyl-5,8-dimethoxy-1,2,3,4-tetrahydronaphthalen-2-yl)acetamide
AMRU-00685-44-9Availableisobenzofuran-1,3-dione
AMRU-007104319-02-0(R)-N-(2-acetyl-5,12-dihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)acetamide
AMRU-00886264-76-8(R)-N-(5,12-dihydroxy-2-(2-methyl-1,3-dioxolan-2-yl)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)acetamide
AMRU-009110267-78-2(1S,5S)-7,14-dihydroxy-3-methyl-5-(2-methyl-1,3-dioxolan-2-yl)-5,6-dihydro-1H-1,5-methanoanthra[2,3-f][1,3]oxazocine-8,13-dione
AMRU-01092395-41-0(7S,9S)-9-acetyl-9-amino-6,7,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione
AMRU-011--
AMRU-012--

Frequently asked questions

What are the approved indications of Amrubicin Hydrochloride?

Approved indications include: Non-small cell lung cancer, Small cell lung cancer.

When does the Amrubicin Hydrochloride patent expire?

No public expiry year is available for Amrubicin Hydrochloride yet; this page updates once verified.

How many synthesis routes are recorded for Amrubicin Hydrochloride?

1 synthesis routes are recorded; the shortest is 10 steps with 1.12 g total yield. Intermediates in each route carry codes and CAS numbers.

Where can I buy Amrubicin Hydrochloride intermediates?

1 intermediate CAS of Amrubicin Hydrochloride are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.

How do I get a quote for Amrubicin Hydrochloride intermediates?

Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.

Source: cross-verified data (structured fields only) · 2026-09-29